Evidence map›Paper›PMID 24350200›Full record

ReviewFrontiers in public health2013

A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel.

Richard E Frye, Daniel Rossignol, Manuel F Casanova, Gregory L Brown, Victoria Martin, Stephen Edelson, Robert Coben, Jeffrey Lewine, John C Slattery, Chrystal Lau and 5 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in public health, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Review
  18. Review
  19. Article
  20. DNA Methylation of the Oxytocin Receptor Across Neurodevelopmental Disorders.Journal of autism and developmental disorders · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Richard E FryeArkansas Children's Hospital Research Institute , Little Rock, AR , USA.
Daniel RossignolRossignol Medical Center , Irvine, CA , USA.
Manuel F CasanovaUniversity of Louisville , Louisville, KY , USA.
Gregory L BrownAutism Recovery and Comprehensive Health Medical Center , Franklin, WI , USA.
Victoria MartinAutism Recovery and Comprehensive Health Medical Center , Franklin, WI , USA.
Stephen EdelsonAutism Research Institute , San Diego, CA , USA.
Robert CobenNew York University Brain Research Laboratory , New York, NY , USA.
Jeffrey LewineMIND Research Network, University of New Mexico , Albuquerque, NM , USA.
John C SlatteryArkansas Children's Hospital Research Institute , Little Rock, AR , USA.
Chrystal LauArkansas Children's Hospital Research Institute , Little Rock, AR , USA.
Paul HardyHardy Healthcare Associates , Hingham, MA , USA.
S Hossein FatemiUniversity of Minnesota Medical School , Minneapolis, MN , USA.
Timothy D FolsomUniversity of Minnesota Medical School , Minneapolis, MN , USA.
Derrick MacfabeUniversity of Western Ontario , London, ON , Canada.
James B AdamsArizona State University , Tempe, AZ , USA.
Arkansas Children's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the fact that seizures are commonly associated with autism spectrum disorder (ASD), the effectiveness of treatments for seizures has not been well studied in individuals with ASD. This manuscript reviews both traditional and novel treatments for seizures associated with ASD. Studies were selected by systematically searching major electronic databases and by a panel of experts that treat ASD individuals. Only a few anti-epileptic drugs (AEDs) have undergone carefully controlled trials in ASD, but these trials examined outcomes other than seizures. Several lines of evidence point to valproate, lamotrigine, and levetiracetam as the most effective and tolerable AEDs for individuals with ASD. Limited evidence supports the use of traditional non-AED treatments, such as the ketogenic and modified Atkins diet, multiple subpial transections, immunomodulation, and neurofeedback treatments. Although specific treatments may be more appropriate for specific genetic and metabolic syndromes associated with ASD and seizures, there are few studies which have documented the effectiveness of treatments for seizures for specific syndromes. Limited evidence supports l-carnitine, multivitamins, and N-acetyl-l-cysteine in mitochondrial disease and dysfunction, folinic acid in cerebral folate abnormalities and early treatment with vigabatrin in tuberous sclerosis complex. Finally, there is limited evidence for a number of novel treatments, particularly magnesium with pyridoxine, omega-3 fatty acids, the gluten-free casein-free diet, and low-frequency repetitive transcranial magnetic simulation. Zinc and l-carnosine are potential novel treatments supported by basic research but not clinical studies. This review demonstrates the wide variety of treatments used to treat seizures in individuals with ASD as well as the striking lack of clinical trials performed to support the use of these treatments. Additional studies concerning these treatments for controlling seizures in individuals with ASD are warranted.

Indexed as

anti-epileptic drugsautism spectrum disorderepilepsygluten-free casein-free dietketogenic dietseizurestreatment

Identifiers

PMID24350200
PMCPMC3859980
OpenAlexW2169588646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.